BARCELONA, Spain—Next generation sequencing is now an essential part of care for glioma in adults, according to research on BRAF targeting as treatment for this disease reported at the 2022 EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium.
Karisa Schreck MD PhD, from Johns Hopkins Hospital, Baltimore, Maryland in the USA talked with Peter Goodwin to discuss her team’s findings from a study looking at the relationship between BRAF oncogene mutations and anti-BRAF therapy outcomes in comparison with pediatric glioma treatment, for which BRAF targeting is already data driven.
She tells the Audio Journal of Oncology how the findings have brought clarity to therapy decision-making with adult patients who have glioma and test positive for BRAF oncogene mutations—and that some of them could potentially be treated with existing BRAF-targeted drugs that have already been licensed for use in other BRAF-driven cancers.
